Germinal Center B Cells Are Essential for Collagen-Induced ArthritisShow others and affiliations
2018 (English)In: Arthritis & Rheumatology, ISSN 2326-5191, E-ISSN 2326-5205, Vol. 70, no 2, p. 193-203Article in journal (Refereed) Published
Abstract [en]
OBJECTIVE: Rheumatoid arthritis (RA) is considered to be a prototypical autoimmune disorder. Several mechanisms have been proposed for the known pathologic function of B cells in RA, including antigen presentation, cytokine secretion, and humoral immunity. The aim of this study was to address the function of B lymphocytes in experimental arthritis.
METHODS: We mapped the adaptive immune response following collagen-induced arthritis (CIA). We subsequently monitored these responses and disease outcomes in genetically modified mouse strains that lack mature B cell or germinal center (GC) functionality in a B cell-intrinsic manner.
RESULTS: Following primary immunization, the draining lymph nodes broadly reacted against type II collagen (CII) with the formation of GCs and T cell activation. Mice that lacked mature B cell function were fully protected against CIA and had a severely attenuated ability to mount isotype-switched humoral immune responses against CII. Almost identical results were observed in mice that were selectively deficient in GC responses. Importantly, GC-deficient mice were fully susceptible to collagen antibody-induced arthritis.
CONCLUSION: We identified GC formation and anticollagen antibody production as the key pathogenic functions of B cells in CIA. The role of B cells in RA is likely to be more complex. However, targeting the GC reaction could allow for therapeutic interventions that are more refined than general B cell depletion.
Place, publisher, year, edition, pages
Hoboken: John Wiley & Sons, 2018. Vol. 70, no 2, p. 193-203
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:hh:diva-48392DOI: 10.1002/art.40354ISI: 000423516200007PubMedID: 29045049Scopus ID: 2-s2.0-85040785650OAI: oai:DiVA.org:hh-48392DiVA, id: diva2:1703115
Funder
Knut and Alice Wallenberg Foundation
Note
Funding agency:
Alex and Eva Wallströms Foundation
European Union Innovative Medicine Initiative
Swedish Strategic Science Foundation
Seventh Framework Programme (FP7)
Medicinska Forskningsrådet (MFR)
2022-10-122022-10-122022-10-13Bibliographically approved